Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma.
Sonia SimonettiMichele IulianiMarco StellatoSilvia CavaliereBruno VincenziGiuseppe ToniniDaniele SantiniFrancesco PantanoPublished in: Journal for immunotherapy of cancer (2022)
Our exploratory study suggests RANKL as a novel independent biomarker of response and survival in patients with mRCC treated with nivolumab.